Science & Enterprise subscription

Follow us on Twitter

  • A biotechnology company designing proteins in food products and therapies for people with food allergies is raising… https://t.co/7vJmrWBgIl
    about 3 hours ago
  • New post on Science and Enterprise: Food Allergy Biotech Raises $40M in New Funds https://t.co/RyXf5JYwpO #Science #Business
    about 3 hours ago
  • Thanks @TrueReply ... much appreciated. https://t.co/8vWabv953x
    about 20 hours ago
  • A large health care system is offering data from its Covid-19 patient registry to a consortium of government and ac… https://t.co/ckWQYtdWM5
    about 23 hours ago
  • New post on Science and Enterprise: Patient Database Offered for Covid-19 Research Group https://t.co/KZQp5rKQ0L #Science #Business
    about 23 hours ago

Please share Science & Enterprise

Moderna Developing Flu, HIV, Nipah Vaccines

Syringe and three vials

Moderna Inc., developer of a currently authorized Covid-19 vaccine, is expanding its vaccine pipeline to cover three more common infectious viral diseases. . . . → Read More: Moderna Developing Flu, HIV, Nipah Vaccines

Drug Price Disruptor Biotech Raises $500M in New Funds

Pills and dollar bill

A start-up biotechnology company that aims to bring drugs to market at lower cost is raising $500 million in its second venture funding round. . . . → Read More: Drug Price Disruptor Biotech Raises $500M in New Funds

Vaccine Shown Active Against New Covid-19 Variants

mRNA vaccine graphic

A current Covid-19 vaccine is shown in lab tests to produce antibodies that appear to protect against new mutations found in South Africa and the U.K. . . . → Read More: Vaccine Shown Active Against New Covid-19 Variants

CureVac, Bayer Partner on Covid-19 Vaccine Supply

Syringe in hand

Vaccine developer CureVac and global drug maker Bayer are partnering on further development, authorization, and supply of CureVac’s Covid-19 vaccine. . . . → Read More: CureVac, Bayer Partner on Covid-19 Vaccine Supply

Synthetic Biology Company Raises $105M in New Funds

DNA chip graphic

A company developing cellular and genetic therapies for cancer designed like electronic circuits is raising $105 million in its second venture round. . . . → Read More: Synthetic Biology Company Raises $105M in New Funds

Synthetic Virus Company Forms, Raises $77M

Adenovirus schematic

A new biotechnology enterprise is underway that develops synthetic viruses attacking solid tumor cancers, based on research at the Salk Institute. . . . → Read More: Synthetic Virus Company Forms, Raises $77M

FDA Issues Precision Genomic Drug Guidance

DNA analysis graphic

The U.S. Food and Drug Administration issued draft administrative and procedural guidelines for genetic disorders treated with precise gene therapies. . . . → Read More: FDA Issues Precision Genomic Drug Guidance

Trial OKed for Rare Disease Gene Therapy

Nerve cells illustration

A start-up biotech company says it received clearance from the Food and Drug Administration to begin a clinical trial of its gene therapy for Krabbe disease. . . . → Read More: Trial OKed for Rare Disease Gene Therapy

A Look Back at 2020 on Science & Enterprise

Covid-19 vaccine infographic

Historians will record 2020 as a pivotal and dangerous time, and our corner of that world at the intersection of science and business played a visible role in it. . . . → Read More: A Look Back at 2020 on Science & Enterprise

Large Covid-19 Vaccine Trial Underway in U.S.

Vaccine vials

A biotechnology vaccine developer began enrolling participants in a large-scale clinical trial testing a vaccine to prevent Covid-19 infections. . . . → Read More: Large Covid-19 Vaccine Trial Underway in U.S.